表紙
市場調查報告書

腦膜炎感染疾病:開發中產品分析

Neisseria meningitidis Infections - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 293895
出版日期 內容資訊 英文 93 Pages
訂單完成後即時交付
價格
腦膜炎感染疾病:開發中產品分析 Neisseria meningitidis Infections - Pipeline Review, H1 2020
出版日期: 2020年04月30日內容資訊: 英文 93 Pages
簡介

腦膜炎感染症是血液及髓膜(腦及脊髓上覆的薄膜)感染細菌的重大疾病,症狀有發燒,頸椎僵直,關節痛,噁心,意識障礙等。風險要素有年齡,抽煙,粘膜病變,人群,乾季·乾旱等天氣,沙塵暴,同時感染呼吸疾病等。

本報告提供全球各國治療腦膜炎感染疾病所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

腦膜炎感染疾病概要

治療藥的開發

  • 腦膜炎感染疾病開發中產品:概要
  • 各企業的開發中產品
  • 各大學/研究機關的開發中產品
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

腦膜炎感染疾病開發治療藥的企業

  • Beijing Minhai Biotechnology Co Ltd
  • Biological E Ltd
  • China National Pharmaceutical Group Corp
  • GlaxoSmithKline Plc
  • Griffith University
  • ImmunoBiology Ltd
  • JN-International Medical Corp
  • MGB Biopharma Ltd
  • Panacea Biotec Ltd
  • Pfizer Inc
  • Sanofi Pasteur SA
  • Serum Institute of India Ltd
  • Wellstat Vaccines LLC

藥物簡介

腦膜炎感染疾病治療藥:開發暫停的產品

腦膜炎感染疾病治療藥:開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC12140IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neisseria meningitidis Infections - Pipeline Review, H1 2020, provides an overview of the Neisseria meningitidis Infections (Infectious Disease) pipeline landscape.

Neisseria Meningitidis is a severe bacterial infection of the bloodstream and meninges (a thin lining covering the brain and spinal cord). Symptoms include fever, neck stiffness, joint pain, nausea, confusion and drowsiness. Risk factors include age, smoking, mucosal lesions, overcrowding, climatic conditions such as dry seasons or prolonged drought and dust storms and concomitant respiratory infections.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neisseria meningitidis Infections - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Neisseria meningitidis Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neisseria meningitidis Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Neisseria meningitidis Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 3, 4, 1, 9, 2 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase 0, Preclinical and Discovery stages comprises 1, 2, 1, 2 and 1 molecules, respectively.

Neisseria meningitidis Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neisseria meningitidis Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Neisseria meningitidis Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neisseria meningitidis Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neisseria meningitidis Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neisseria meningitidis Infections (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neisseria meningitidis Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neisseria meningitidis Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Neisseria meningitidis Infections - Overview
  • Neisseria meningitidis Infections - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Neisseria meningitidis Infections - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Neisseria meningitidis Infections - Companies Involved in Therapeutics Development
  • Beijing Minhai Biotechnology Co Ltd
  • Bioworld Technologies Sdn Bhd
  • CanSino Biologics Inc
  • Chongqing Zhifei Biological Products Co Ltd
  • GlaxoSmithKline Plc
  • Hilleman Laboratories Pvt Ltd
  • ImmunoBiology Ltd
  • Johnson & Johnson
  • Neoculi Pty Ltd
  • Novo Medi Sciences Pvt Ltd
  • Omvax Inc
  • Pfizer Inc
  • ReAlta Life Sciences Inc
  • Sanofi Pasteur SA
  • Serum Institute of India Ltd
  • Wellstat Vaccines LLC
  • Neisseria meningitidis Infections - Drug Profiles
  • (diphtheria + haemophilus influenza [serotype B] + meningococcal + pertussis (acellular) + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (Haemophilus influenzae B + Neisseria meningitidis [serotypes A, C, Y, W135]) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (meningococcal [serotypes A, C, W-135, X, Y] (pentavalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ACYW-135 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MenBioVax - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • meningococcal [serotype B] vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • meningococcal [serotype B] vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • meningococcal [serotype B] vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • meningococcal [serotype B] vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • meningococcal [serotype B] vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • meningococcal [serotype B] vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • meningococcal [serotype B] vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • meningococcal [serotypes A, B, C] vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • meningococcal [serotypes A, C, W-135, Y] (quadrivalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine 2 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • meningococcal [serotypes A, C] (bivalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • meningococcal [serotypes C, Y] vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • meningococcal [serotypes C] vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • meningococcal [strain C2135] vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • meningococcal vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • meningococcal vaccine 1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NCL-195 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Neisseria meningitidis [serotype B] vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PF-06886992 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RLS-0071 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TP-10 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Neisseria meningitidis Infections - Dormant Projects
  • Neisseria meningitidis Infections - Discontinued Products
  • Neisseria meningitidis Infections - Product Development Milestones
  • Featured News & Press Releases
  • Aug 29, 2019: $440 million funding boost for vital health and medical research for all stages of life
  • Nov 28, 2018: NIHR supports world-first trial of new nose drop to fight meningitis
  • Jun 27, 2018: European approval for lower dose of GSk's Meningitis vaccine
  • Jun 18, 2018: New way to determine protection of Men B vaccine against different strains
  • Apr 23, 2018: Pfizer Granted FDA Breakthrough Therapy Designation for TRUMENBA (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Children Ages 1 to 9 Years
  • Mar 06, 2018: TRUMENBA (Meningococcal Group B Vaccine) Now Available In Canada
  • Feb 07, 2018: GSK's meningitis B vaccine Bexsero receives Breakthrough Therapy Designation from US FDA for prevention of Invasive Meningococcal Disease in children 2-10 years of age
  • Dec 13, 2017: Phase 3 TRUMENBA (Meningococcal Group B Vaccine) Data Published In New England Journal Of Medicine Demonstrate The Vaccine's Immunogenicity
  • Nov 22, 2017: Meningococcal Vaccine Antigens expressed by 91 Percent of Tested Bacterial Strains
  • Sep 12, 2017: TGA approves MENVEO vaccine to help protect babies from two months old from meningococcal disease
  • Jul 11, 2017: Recall of MENVEO [Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine] Solution for intramuscular injection
  • May 30, 2017: European Commission Approves Pfizer's Trumenba To Help Prevent Meningococcal Group B Disease In Adolescents And Adults
  • May 15, 2017: GlaxoSmithKline Announces (meningococcal B) vaccine availability
  • Mar 24, 2017: Pfizer Receives Positive CHMP Opinion for TRUMENBA for Prevention of Meningococcal Group B Disease
  • Mar 24, 2017: GSK Announces Availability of Menveo (meningococcal ACWY vaccine)
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Neisseria meningitidis Infections, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Neisseria meningitidis Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2020
  • Neisseria meningitidis Infections - Pipeline by Bioworld Technologies Sdn Bhd, H1 2020
  • Neisseria meningitidis Infections - Pipeline by CanSino Biologics Inc, H1 2020
  • Neisseria meningitidis Infections - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2020
  • Neisseria meningitidis Infections - Pipeline by GlaxoSmithKline Plc, H1 2020
  • Neisseria meningitidis Infections - Pipeline by Hilleman Laboratories Pvt Ltd, H1 2020
  • Neisseria meningitidis Infections - Pipeline by ImmunoBiology Ltd, H1 2020
  • Neisseria meningitidis Infections - Pipeline by Johnson & Johnson, H1 2020
  • Neisseria meningitidis Infections - Pipeline by Neoculi Pty Ltd, H1 2020
  • Neisseria meningitidis Infections - Pipeline by Novo Medi Sciences Pvt Ltd, H1 2020
  • Neisseria meningitidis Infections - Pipeline by Omvax Inc, H1 2020
  • Neisseria meningitidis Infections - Pipeline by Pfizer Inc, H1 2020
  • Neisseria meningitidis Infections - Pipeline by ReAlta Life Sciences Inc, H1 2020
  • Neisseria meningitidis Infections - Pipeline by Sanofi Pasteur SA, H1 2020
  • Neisseria meningitidis Infections - Pipeline by Serum Institute of India Ltd, H1 2020
  • Neisseria meningitidis Infections - Pipeline by Wellstat Vaccines LLC, H1 2020
  • Neisseria meningitidis Infections - Dormant Projects, H1 2020
  • Neisseria meningitidis Infections - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Neisseria meningitidis Infections - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Neisseria meningitidis Infections - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Neisseria meningitidis Infections, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020